What topics does this cannabis study cover?

This study covers research on: CBD.

CBD

Cannabinoids' surprising impact on male hormone production revealed

Q: What did this research study find?

**Both THC and CBD significantly reduce production of male hormones** in human adrenal cells

Q: Where was this research published?

Published in Biochemical and biophysical research communications on January 25, 2026.

Tetrahydrocannabinol (THC) and cannabidiol (CBD) inhibit androgen biosynthesis in H295R cells.

Biochemical and biophysical research communications • January 25, 2026 • Moderately Relevant

🤖

AI Summary

In a groundbreaking study exploring the complex relationship between cannabinoids and human reproductive biology, researchers investigated how THC and CBD impact androgen production. Using human adrenal cells (H295R), the scientists discovered that both tetrahydrocannabinol and cannabidiol significantly reduce the synthesis of key male hormones, including DHEA, androstenedione, and testosterone.

The research revealed that these phytocannabinoids inhibit hormone production through a mechanism that is independent of traditional cannabinoid receptors. Notably, CBD demonstrated a unique ability to interfere with the CYP17A1 enzyme, which plays a critical role in steroid hormone synthesis. While previous observations suggested higher testosterone levels in cannabis users, this study challenges that assumption by providing direct evidence of cannabinoids' inhibitory effect on androgen biosynthesis.

These findings carry important implications for reproductive health, particularly given the widespread use of cannabis among men of reproductive age. The research highlights the need for further investigation into how cannabinoids might impact male fertility, suggesting that cannabis consumption could potentially influence hormonal balance in ways not previously understood.

💡 Key Findings

Both THC and CBD significantly reduce production of male hormones in human adrenal cells

High

85%

CBD shows unique interference with CYP17A1 enzyme in steroid hormone synthesis

Good

75%

Hormone inhibition occurs independent of traditional cannabinoid receptors

High

80%

📄 Original Abstract

The role of the cannabinoid system in human reproduction, and particularly in androgen biosynthesis, remains highly controversial. We recently observed significantly higher serum concentrations of testosterone and androstenedione in cannabis users than in the control group of a cohort of young Swiss men. To determine whether there is a direct causal relationship between cannabinoid exposure and androgen levels, we tested in vitro the effect of tetrahydrocannabinol (THC) and cannabidiol (CBD) on androgen biosynthesis in H295R cells. Modulation of steroidogenesis by phytocannabinoids and other agents was analysed in cell culture medium by liquid chromatography coupled to tandem mass spectrometry. Both THC and CBD significantly reduced in vitro DHEA, androstenedione and testosterone production by H295R cells in a concentration-dependent manner. The inhibitory action of cannabinoids was rapid and affected principally late steps of steroidogenesis. It was not prevented by rimonabant, a specific antagonist of the CB1 cannabinoid receptor. In addition, CBD (but not THC) appeared to affect the steroidogenic step involving the CYP17A1 enzyme. These results exclude a direct stimulation of steroidogenesis by phytocannabinoids in vivo as a putative mechanism for the positive association observed between cannabis use and blood androgen concentration in young men. Alternative explanations are discussed. Given that cannabis is frequently consumed by men of reproductive age, a better understanding of THC and CBD action on the reproductive system seems highly relevant in the context of the decline in male fertility observed in the general population.

Paper Type

📄 Research

Publication

Journal: Biochemical and biophysical research communications
Published: January 25, 2026
PMID: 41447880
DOI: 10.1016/j.bbrc.2025.153179

Authors (5)

Fanny Zufferey Service of Clinical Chemistry & Toxicology, Central Institute of Hospitals, Hospital of Valais, Sion, Switzerland. Electronic address: fanny.zufferey@hopitalvs.ch.
Doriane Hebinger Laboratory of Clinical Research, Central Institute of Hospitals, Hospital of Valais, Sion, Switzerland. Electronic address: doriane.hebinger@hopitalvs.ch.
Anne-Claire Brossaud Laboratory of Clinical Research, Central Institute of Hospitals, Hospital of Valais, Sion, Switzerland. Electronic address: anne-claire.brossaud@hopitalvs.ch.
Laura Millius Service of Clinical Chemistry & Toxicology, Central Institute of Hospitals, Hospital of Valais, Sion, Switzerland. Electronic address: laura.millius@hopitalvs.ch.
Michel F Rossier Service of Clinical Chemistry & Toxicology, Central Institute of Hospitals, Hospital of Valais, Sion, Switzerland; Department of Internal Medicine, Geneva University Faculty of Medicine, Geneva, Switzerland. Electronic address: michel.rossier@unige.ch.